Anti-Toxoplasma gondii effect of two spider venoms in vitro and in vivo
Anti-Toxoplasma gondii effect of two spider venoms in vitro and in vivo
复制标题
两种蜘蛛毒的体内外抗弓形虫作用
DOI：
10.1016/j.toxicon.2019.05.003
复制
发表时间：
2019-08-01
期刊：
影响因子：
2.8
通讯作者：
Jiang, Liping
中科院分区：
文献类型：
--
作者：
Hou, Shengjie;Liu, Yuan;Jiang, Liping
弓形虫是引起严重公共卫生问题的重要病原体。目前，治疗弓形虫病的药物副作用严重，迫切需要研究更有效、毒性相对较低的新物质。蜘蛛毒液含有多种新的药理化合物。然而，抗T。蜘蛛毒液的弓形虫活性在很大程度上仍不清楚。本实验研究了虎纹夜蛾(Ornitoctonus huwena，HWVM)和京照斑潜蝇(Chilobrachys京照，JZVM)蜘蛛蛇毒对弓形虫速殖子的体内外抗寄生虫作用。用四甲基偶氮唑蓝比色法测定HWVM和JZVM对HeLa细胞的杀伤活性。低剂量(3.125、6.2 5和12.5mU g/m L)人参总皂甙和降脂微球对HeLa细胞的毒性较低。台盼蓝排斥试验表明，HWVM和JZVM均以时间依赖的方式影响速殖子的存活率。两种蜘蛛毒素在体外均能抑制速殖子的入侵和增殖(p<；0.05)。此外，在感染2×10(3)弓形虫速殖子后接受HWVM治疗的小鼠显示出比只接受生理盐水治疗的小鼠更好的存活率(p<；0.05)，而JZVM治疗的小鼠则没有。我们的研究结果表明，HWVM是治疗弓形虫病的一种有前途的药物。
Toxoplasma gondii (T. gondii) is an important pathogen that can cause serious public health problems. Currently, therapeutic drugs for toxoplasmosis present serious side effects, researches on more effective and novel substances with relatively low toxicity are urgently needed. Spider venoms comprise diverse novel pharmacological compounds. However, the anti-T. gondii activity of spider venoms remains largely unknown. This study was carried out to evaluate the anti-parasitic effect of spider venoms from Ornitoctonus huwena (HWVM) and Chilobrachys jingzhao (JZVM) against T. gondii tachyzoites in vitro and in vivo. Cytotoxic activity of HWVM and JZVM to HeLa cells was determined by MTT cell viability assays. Low doses (3.125, 6.25 and 12.5 mu g/mL) of HWVM and JZVM displayed low toxicity to HeLa cells. Trypan blue exclusion assay indicated that either of HWVM and JZVM affected the viability of tachyzoites in a time-dependent manner. Both spider venoms inhibited the invasion and proliferation of tachyzoites in vitro (p < 0.05). Moreover, Mice treated with HWVM after infection with 2 x 10(3) T. gondii tachyzoites showed a better survival rate than mice treated with saline alone (p < 0.05), while mice treated with JZVM did not. Our findings indicate that HWVM is a promising agent for the treatment of toxoplasmosis.